BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bai Y, Jin J, Zhou W, Zhang S, Xu J. The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 2021;31:1365-74. [PMID: 33812735 DOI: 10.1016/j.numecd.2021.02.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Weng YF, Chen CY, Hwang SJ, Huang YB. Evaluation of sodium-glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics. Kaohsiung J Med Sci 2023. [PMID: 36625282 DOI: 10.1002/kjm2.12635] [Reference Citation Analysis]
2 Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol 2022;21:83. [PMID: 35614469 DOI: 10.1186/s12933-022-01512-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Scheen AJ, Delanaye P. Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers. Diabetes Metab 2021;48:101315. [PMID: 34910981 DOI: 10.1016/j.diabet.2021.101315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Delanaye P, Scheen AJ. Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies. Diabetes Epidemiology and Management 2021;3:100021. [DOI: 10.1016/j.deman.2021.100021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]